Clinical Trials — Gynecologic Cancer

                                                                                            Click on trial for contact information and description.

                                                                                            Click for contact information on Phase III trials.

 

A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer

 

A Phase II Single Arm Study of Carboplatin and DOXIL (PLD) Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

 

A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma (This study is ongoing, but currently not recruiting patients.)

 

A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma (This study is ongoing, but currently not recruiting patients.)

 

Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer

 

A Randomized Phase II Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination, Versus PLD Alone, in Subjects With Platinum-Resistant Ovarian Cancer

 

A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients With Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

 

A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum

 

Phase II Study of Faslodex In Recurrent/Metastatic Endometrial Cancer (This study is ongoing but currently not recruiting patients.)

 

A Phase II Evaluation Of Irofulven (IND #55804, NSC #683863) In The Treatment Of Recurrent Or Persistent Platinium-Sensitive Ovarian Or Primary Peritoneal Cancer (This study is ongoing, but currently not recruiting patients.)

 

A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus (This study is ongoing, but currently not recruiting patients.)

 

A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas (This study is ongoing, but currently not recruiting patients.)

 

Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer

 

A Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) when administered to Patients with Advanced Solid Tumors

 

Phase III Clinical Trials for Gynecologic Cancer are also available. 

        

For more information, contact:

Lisa Hatch, RN, BSN
             or
Donna Wheatley, LPN

Office: (706) 721-8981

[Back to Top]